DERM

Company Overview — What Does Journey Medical Corp Do?

Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant acne; Targadox, an oral doxycycline drug for adjunctive therapy for severe acne; Ximino, an oral minocycline drug for the treatment of moderate to severe acne; and Exelderm cream and solution for topical use. It also sells doxycycline hyclate tablets, minocycline hydrocholoride capsules, and sulconazole nitrate cream and solution. The company was formerly known as Coronado Dermatology, Inc. and changed its name to Journey Medical Corporation. Journey Medical Corporation was incorporated in 2014 and is headquartered in Scottsdale, Arizona. Journey Medical Corp (DERM) is classified as a micro-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO Claude Maraoui and employs approximately 90 people. With a market capitalization of $127M, DERM is one of the notable companies in the Healthcare sector.

Journey Medical Corp (DERM) Stock Rating — Reduce (April 2026)

As of April 2026, Journey Medical Corp receives a Reduce rating with a composite score of 34.8/100 and 2 out of 5 stars from the Blank Capital Research quantitative model.DERM ranks #3,562 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, Journey Medical Corp ranks #568 of 838 stocks, placing it in the lower half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

DERM Stock Price and 52-Week Range

Journey Medical Corp (DERM) currently trades at $5.17. The stock lost $0.02 (0.4%) in the most recent trading session. The 52-week high for DERM is $9.55, which means the stock is currently trading -45.9% from its annual peak. The 52-week low is $5.40, putting the stock -4.3% above its annual trough. Recent trading volume was 183K shares, suggesting relatively thin trading activity.

Is DERM Overvalued or Undervalued? — Valuation Analysis

Journey Medical Corp (DERM) carries a value factor score of 27/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-book ratio stands at 4.25x, versus the sector average of 2.75x. The price-to-sales ratio is 2.24x, compared to 1.66x for the average Healthcare stock.

At current multiples, Journey Medical Corp trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

Journey Medical Corp Profitability — ROE, Margins, and Quality Score

Journey Medical Corp (DERM) earns a quality factor score of 33/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -39.5%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -13.3% versus the sector average of -33.1%.

On a margin basis, Journey Medical Corp reports gross margins of 63.9%, compared to 71.5% for the sector. The operating margin is -18.2% (sector: -66.1%). Net profit margin stands at -21.4%, versus -58.7% for the average Healthcare stock. Revenue growth is running at 18.7% on a trailing basis, compared to 10.6% for the sector. Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

DERM Debt, Balance Sheet, and Financial Health

Journey Medical Corp has a debt-to-equity ratio of 79.0%, compared to the Healthcare sector average of 32.0%. Leverage is within a manageable range for the industry, though investors should monitor debt trends over time. The current ratio is 1.79x, suggesting adequate working capital coverage. Total debt on the balance sheet is $25M. Cash and equivalents stand at $25M.

DERM has a beta of 0.99, meaning it is roughly in line with the broader market in terms of price volatility. The stability factor score for Journey Medical Corp is 33/100, suggesting elevated price swings that may be unsuitable for conservative portfolios.

Journey Medical Corp Revenue and Earnings History — Quarterly Trend

In TTM 2026, Journey Medical Corp reported revenue of $60M and earnings per share (EPS) of $-0.47. Net income for the quarter was $-13M. Gross margin was 63.9%. Operating income came in at $-11M.

In FY 2025, Journey Medical Corp reported revenue of $62M and earnings per share (EPS) of $-0.47. Net income for the quarter was $-11M. Gross margin was 66.2%. Revenue grew 10.2% year-over-year compared to FY 2024. Operating income came in at $-8M.

In Q3 2025, Journey Medical Corp reported revenue of $18M and earnings per share (EPS) of $-0.09. Net income for the quarter was $-2M. Revenue grew 20.5% year-over-year compared to Q3 2024. Operating income came in at $-2M.

In Q2 2025, Journey Medical Corp reported revenue of $15M and earnings per share (EPS) of $-0.16. Net income for the quarter was $-4M. Revenue grew 1.0% year-over-year compared to Q2 2024. Operating income came in at $-3M.

Over the past 8 quarters, Journey Medical Corp has demonstrated a growth trajectory, with revenue expanding from $15M to $60M. Investors analyzing DERM stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

DERM Dividend Yield and Income Analysis

Journey Medical Corp (DERM) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

DERM Momentum and Technical Analysis Profile

Journey Medical Corp (DERM) has a momentum factor score of 36/100, signaling weak relative price performance. Stocks with low momentum scores have historically tended to continue underperforming in the near term. The investment factor score is 26/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 61/100 reflects moderate short selling activity.

DERM vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, Journey Medical Corp (DERM) ranks #568 out of 838 stocks based on the Blank Capital composite score. This places DERM in the lower half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing DERM against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full DERM vs S&P 500 (SPY) comparison to assess how Journey Medical Corp stacks up against the broader market across all factor dimensions.

DERM Next Earnings Date

No upcoming earnings date has been announced for Journey Medical Corp (DERM) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy DERM? — Investment Thesis Summary

The quantitative profile for Journey Medical Corp suggests caution. The quality score of 33/100 flags below-average profitability. The value score of 27/100 indicates premium valuation. Momentum is weak at 36/100, a headwind for near-term performance. High volatility (stability score 33/100) increases portfolio risk.

In summary, Journey Medical Corp (DERM) earns a Reduce rating with a composite score of 34.8/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on DERM stock.

Related Resources for DERM Investors

Explore more research and tools: DERM vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare DERM head-to-head with peers: DERM vs AZN, DERM vs SLGL, DERM vs VMD.